{"news_desk": "Dealbook", "print_page": "", "section_name": "Business Day", "subsection_name": "DealBook", "byline": {"original": "By ROBERT CYRAN", "person": [{"rank": 1, "role": "reported", "firstname": "Robert", "organization": "", "lastname": "CYRAN"}]}, "abstract": null, "type_of_material": "News", "word_count": "378", "lead_paragraph": "With a $21 billion deal, the pharmaceutical giant gets a blockbuster drug, but at a high cost: It must share profits with rival Johnson & Johnson.", "pub_date": "2015-03-06T00:00:00Z", "document_type": "article", "slideshow_credits": null, "headline": {"main": "Why AbbVie May Have Overpaid for Cancer Drug Maker", "content_kicker": "Breakingviews", "kicker": "Breakingviews"}, "snippet": "With a $21 billion deal, the pharmaceutical giant gets a blockbuster drug, but at a high cost: It must share profits with rival Johnson & Johnson.", "multimedia": [], "web_url": "http://www.nytimes.com/2015/03/06/business/dealbook/why-abbvie-may-have-overpaid.html", "keywords": [{"rank": "1", "is_major": "N", "value": "Mergers, Acquisitions and Divestitures", "name": "subject"}, {"rank": "2", "is_major": "N", "value": "Drugs (Pharmaceuticals)", "name": "subject"}, {"rank": "3", "is_major": "N", "value": "Biotechnology and Bioengineering", "name": "subject"}, {"rank": "4", "is_major": "N", "value": "Pharmacyclics, Incorporated", "name": "organizations"}, {"rank": "5", "is_major": "N", "value": "AbbVie Inc", "name": "organizations"}, {"rank": "6", "is_major": "N", "value": "Johnson & Johnson", "name": "organizations"}, {"rank": "7", "is_major": "N", "value": "Shire PLC", "name": "organizations"}], "blog": [], "_id": "54f8bb4738f0d81f0d7a60c8", "source": "The New York Times"}